Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, has announced that it will hold investor calls to provide updates on its mRNA therapeutic vaccine programs. The company's mRNA platform has shown promise in both preventive and therapeutic vaccine development, with a strong focus on personalized cancer vaccines and infectious disease applications.

Everest Medicines' mRNA platform offers several advantages over other mRNA vaccine technologies, including safety, efficacy, and scalability. The platform's use of lipid nanoparticle (LNP) delivery systems, strong preclinical data, and potential for rapid and large-scale production make it well-suited for the development of innovative vaccines and medicines. The company's strategic partnerships, such as with China Resources Pharmaceutical Group, have helped navigate regulatory pathways and accelerate commercialization.

The company's personalized mRNA cancer vaccine program, EVM16, is currently in a first-in-human (FIH) clinical trial at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. This trial is designed to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with PD-1 antibody for patients with advanced or recurrent solid tumors. Preclinical studies have shown that EVM16 stimulates a strong neoantigen-specific T cell response and inhibits tumor growth, with the combination of EVM16 and a PD-1 antibody demonstrating synergistic effects.

Everest Medicines' mRNA platform has also shown promise in the development of preventive vaccines. In a head-to-head Phase II clinical study conducted by Providence, Everest's monovalent COVID-19 vaccine candidate PTX-COVID19-B was statistically non-inferior to Pfizer/BioNTech's Comirnaty® in terms of safety and efficacy. The company is also developing an Omicron-based bivalent booster candidate, EVER-COVID19-M1.2, which aims to provide broad-spectrum protection against emerging variants.

Everest Medicines' mRNA therapeutic vaccines have the potential to address critical unmet medical needs in infectious diseases and cancer, fitting into the broader landscape of biopharmaceutical innovation. The global mRNA vaccines market is expected to grow at a CAGR of 24.7% from 2021 to 2028, reaching USD 16.5 billion by 2028. The global cancer immunotherapy market is projected to reach USD 240.9 billion by 2027, growing at a CAGR of 11.2% during the forecast period. The global infectious diseases market is expected to reach USD 114.3 billion by 2027, growing at a CAGR of 5.4% during the forecast period.

Everest Medicines' investor calls will provide an opportunity for investors to learn more about the company's mRNA therapeutic vaccine programs, their potential market opportunities, and the company's strategic goals. The company's commitment to developing innovative mRNA immunotherapies for cancer and autoimmune diseases, as well as its focus on establishing leadership positions in nephrology, infectious disease, and autoimmune diseases, positions it well to capitalize on the growing demand for innovative vaccines and medicines.